19-896 Phase III
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib (LOXO-292) to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naive, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (View details on clinicaltrial.gov)